Role of 5-HT receptors in treatment of overactive bladder

被引:11
作者
Khaled, SM [1 ]
Elhilali, M [1 ]
机构
[1] McGill Univ, Dept Urol, Montreal, PQ, Canada
关键词
D O I
10.1358/dot.2003.39.8.799407
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Normal bladder function requires coordinated detrusor relaxation and urethral sphincter contraction during the filling phase and the reverse during micturition. This is achieved by the integration of excitatory, inhibitory, and sensory nerve activity in control centers in the spinal cord, pons, and forebrain. It is possible that much of bladder pathology is related to disturbances in the vesical ganglia, sensory reflex loops, and central control of micturition. Experimental studies in animals have revealed that spinal reflex circuits involved in voiding function exhibit a dense serotonergic innervation, multiple 5-HT receptors, and sensitivity to 5-HT receptor agonists and antagonists, and 5-HT reuptake inhibitors. Activity in the serotonergic pathway generally enhances urine storage by facilitating the vesical sympathetic reflex pathway and inhibiting the parasympathetic voiding pathway. Thus, 5-HT receptor antagonists and reuptake inhibitors represent important targets for the development of new treatments of detrusor overactivity and urinary incontinence. Among the drugs modulating the bladder function through 5-HT receptor, duloxetine, a potent and selective inhibitor of 5-HT and NE reuptake, is presently undergoing clinical trials for stress urinary incontinence after being shown to be effective in animal models of this condition. (C) 2003 Prous Science. All rights reserved.
引用
收藏
页码:599 / 607
页数:9
相关论文
共 59 条
[1]   Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence [J].
Anderson, RU ;
Mobley, D ;
Blank, B ;
Saltzstein, D ;
Susset, J ;
Brown, JS .
JOURNAL OF UROLOGY, 1999, 161 (06) :1809-1812
[2]   Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis [J].
Appell, RA .
UROLOGY, 1997, 50 (6A) :90-96
[3]   A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin [J].
Birns, J ;
Lukkari, E ;
Malone-Lee, JG .
BJU INTERNATIONAL, 2000, 85 (07) :793-798
[4]   THE 5-HT4 RECEPTOR - A PLACE IN THE SUN [J].
BOCKAERT, J ;
FOZARD, JR ;
DUMUIS, A ;
CLARKE, DE .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1992, 13 (04) :141-145
[5]   The role of α1-adrenoceptors and 5-HT1A receptors in the control of the micturition reflex in male anaesthetized rats [J].
Conley, RK ;
Williams, TJ ;
Ford, APDW ;
Ramage, AG .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 133 (01) :61-72
[6]  
DAHLSTRO.A, 1965, ACTA PHYSIOL SCAND, VS 64, P7
[7]  
DAHLSTROM A, 1964, ACTA PHYSIOL SCAND, V62, P1
[8]  
de Groat WC, 1993, NERVOUS CONTROL UROG, V3, P227
[9]  
de Groat WC, 1979, INTEGRATIVE FUNCTION, P50
[10]  
DRUTZ H, 1999, J PELVIC FLOOD DYSFU, V10, P283